Publications

  • Endothelial alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF. Am.

    da Silva R.G., Tavora B., Robinson S.D., Reynolds L.E., Szekeres C., Lamar J., Batista S., Kostourou V., Germain M.A., Reynolds A.R., Jones D.T., Watson A.R., Jones J.L., Harris A., Hart I.R., Iruela-Arispe M.L., Dipersio C.M., Kreidberg J.A., Hodivala-Dilke K.M. (2010).

     

    J. Pathol. 2010 Sep;177(3):1534-48.

  • Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib.

    Welti J.C., Gourlaouen M., Powles T., Kudahetti S.C., Wilson P., Berney D.M., Reynolds A.R. (2010)

    Oncogene, 2010 Nov 8

  • Potential relevance of bell-shaped and U-shaped dose-responses for the anti-angiogenic therapy of cancer.

    Reynolds A.R. (2010).

    Dose Response 8(3):253-284.

  • Alphavbeta3-integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis.

    Authors: Robinson SD, Reynolds LE, Kostourou V, Reynolds A.R., da Silva RG, Tavora B, Baker M, Marshall JF, Hodivala-Dilke KM. (2009).

    J. Biol. Chem. 4:284(49):33966-81

  • Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.

    Authors: Reynolds, A.R., Hart, I.R., Watson, A., Welti, J., Silva, R., Salih, M., Jones, M.C., Jones D.T., Gourlaouen, M., Saunders, G., Da Violante, G., Robinson, S.D., Kostourou, V., Perron-Sierra, F., Norman, J.C., Tucker, G.C. & Hodivala-Dilke, K.M.

    Nature Medicine 15, 392-400 (2009).

  • Will integrin inhibitors have proangiogenic effects in the clinic?

    Authors: Reynolds A.R. & Hodivala-Dilke K.M. (2009)

    Reply. Nature Medicine 15(7):727

  • Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis.

    Authors: Scott A, Nayak V, Hetheridge C, Reynolds A.R., Hodivala-Dilke K.M. and Mellor H.

    Angiogenesis (2008) 11(4):337-46.

  • Activation of PPARβ/δ induces endothelial cell proliferation and angiogenesis. Atheriosclerosis,

    Authors: Piqueras L., Reynolds A.R., Hodivala-Dilke K.M., Alfranca A., Redondo J.M., Hatae T., Tanabe T., Warner T.D. and Bishop-Bailey D.

    Thrombosis and Vascular Biology (2007) 27(1):63-9.

  • Bone marrow cells engraft within the epidermis and proliferate in vivo with no evidence of cell fusion.

    Authors: Brittan M., Braun K.M., Reynolds L.E., Conti F.J., Reynolds A.R., Poulsom R., Alison M.R., Wright N.A., Hodivala-Dilke K.M

    Journal of Patholology (2005) 205(1):1-13.

  • Elevated Flk1 (VEGF receptor 2) signalling mediates enhanced angiogenesis in 3-integrin-deficient mice.

    Authors: Reynolds A.R., Reynolds L.E., Nagel T.E., Lively J.C., Robinson S.D., Hicklin D.J., Bodary S.C., Hodivala-Dilke K.M.

    Cancer Research (2004) 64(23):8643-50.

  • EGFR activation coupled to inhibition of tyrosine phosphatases causes lateral signal propagation.

    Authors: Reynolds A.R., Tischer C., Verveer P.J., Rocks O., Bastiaens P.I.

    Nature Cell Biology (2003) 5(5):447-53.

  • Integrins in angiogenesis: multitalented molecules in a balancing act.

    Authors: Hodivala-Dilke K.M., Reynolds A.R., Reynolds L.E.

    Cell and Tissue Research (2003) 314(1):131-44.

  • Nanoparticle-mediated gene delivery to tumour neovasculature.

    Authors: Reynolds A.R., Moein Moghimi S., Hodivala-Dilke K.M.

    Trends in Molecular Medicine (2003) 9(1):2-4.

  • Quantitative imaging of lateral ErbB1 receptor signal propagation in the plasma membrane.

    Authors: Verveer P.J., Wouters F.S., Reynolds A.R., Bastiaens P.I.

    Science (2000) 290(5496):1567-70.

  • 1